Panoma Therapeutics, Inc., is developing first-in-class small molecule therapeutics that directly target a novel mechanism that disrupts a critical MYC interaction, restoring MYC degradation. MYC is deregulated in greater than seventy (>70%) of all cancers and is a long-standing and highly validated oncology target. No other company has been able to properly disrupt MYC as a key driver/oncogene in cancer because it has no druggable pockets. Panoma Therapeutics has drugged this undruggable target.

The Company has two first-in-class leading development candidates using this proprietary approach and has composition of matter IP and broad rights to other compounds using this novel mechanism. Panoma is advancing toward IND filing, and the start of Phase I clinical trials in genetically defined and company validated MYC-driven hematologic malignancies. The goal of demonstrating selective pathway inhibition and proof-of-concept in patients will not only translate into fast to market commercial opportunities, but potential expansion in a broad array of liquid and solid MYC driven cancers which represents a multi-billion-dollar opportunity.

Panoma is in the process of raising $100 million Series A financing to fund a capital-efficient clinical strategy to deliver significant strategic and equity value by the close of Series A on Phase Ib data. The company was spun out of Transition Bio. Inc. (a discovery company) and is based on pioneering research from the University of Cambridge (UK) and Harvard University.